News

Additionally, iodixanol may save up to $616 on average per patient vs. Ioxaglate in high-risk inpatient MACE-related costs, but no difference in non high-risk patients. Conclusions: MACE is a ...
Did you know that certain medications can cause symptom of 'Disseminated intravascular coagulation'. Find these drugs listed on the page and be warned of similar symptoms as possible side-effects.
Did you know that certain medications can cause symptom of 'Maculo-Popular Rash'. Find these drugs listed on the page and be warned of similar symptoms as possible side-effects.
At 30 days, there was one death in the ioxaglate group (1.4%) vs. four in the iodixanol group (5.7%; RR = 0.24; 95% CI, 0.03-2.06). Acute renal failure occurred in 18 patients in the ioxaglate ...
The Food and Drug Administration (FDA) has reported that Hexabrix (ioxaglate meglumine, ioxaglate sodium; Guerbet LLC), a medical imaging agent. Hexabrix is a radiopaque contrast medium indicated ...
Of these, 45,485 received the iso-osmolar contrast medium iodixanol and 12,440 received the low-osmolar contrast medium ioxaglate.
Hexabrix 320 is a sterile, nonpyrogenic, aqueous solution consisting of 39.3% (wt/vol) ioxaglate meglumine and 19.6% (wt/vol) ioxaglate sodium. Dissociated ioxaglate provides six iodine atoms per ...
WASHINGTON, October 27 /PRNewswire/ -- Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) (Iodixanol) were no different in regard to ...
Two new studies have shown that there is no difference in the incidence of contrast-induced nephropathy when either an iso-osmolar or low-osmolar contrast agent was used in patients undergoing ...
Compared with ioxaglate, iodixanol did not significantly reduce the increase in serum creatinine levels after coronary catheterization or PCI, said Mehran.
Mean contrast used was 204 cc in the ioxaglate group and 217 cc in the iodixanol group. Mean duration of contrast administration was approximately 50 minutes. N-acetyl-cysteine was used in 72% of ...